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OBJECTIVE— To evaluate the association between 25-hydroxyvitamin D [25(OH)D] and
metabolic syndrome in the Chinese population.
RESEARCH DESIGN ANDMETHODS— Plasma 25(OH)D was measured in a cross-
sectional sample of 1,443 men and 1,819 women aged 50–70 years from Beijing and Shanghai.
Metabolic syndrome was defined according to the updated National Cholesterol Education
Program Adult Treatment Panel III criteria for Asian Americans. Fasting plasma glucose, insulin,
lipid profile, A1C, and inflammatory markers were measured.
RESULTS— The geometric mean of plasma 25(OH)D was 40.4 nmol/l, and percentages of
vitamin D deficiency [25(OH)D 50 nmol/l] and insufficiency [50  25(OH)D 75 nmol/l]
were 69.2 and 24.4%, respectively. Compared with the highest 25(OH)D quintile (57.7
nmol/l), the odds ratio for metabolic syndrome in the lowest quintile (28.7 nmol/l) was 1.52
(95% CI 1.17–1.98, Ptrend 0.0002) after multiple adjustment. Significant inverse associations
also existed between 25(OH)D and individual metabolic syndrome components plus A1C.
Moreover, we observed significant inverse associations of 25(OH)D with fasting insulin and the
insulin resistance index (homeostasis model assessment of insulin resistance [HOMA-IR]) in
overweight and obese individuals (BMI24 kg/m2) but not in their normal-weight counterparts
(test for interaction: P  0.0363 and 0.0187 for insulin and HOMA-IR, respectively).
CONCLUSIONS— Vitamin D deficiency is common in the middle-aged and elderly Chi-
nese population, and a low 25(OH)D level is significantly associated with an increased risk of
having metabolic syndrome and insulin resistance. Prospective studies and randomized clinical
trials are warranted to determine the role of 25(OH)D in the development of metabolic syndrome
and related metabolic diseases.
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V itamin D deficiency is now recog-nized as a worldwide concern (1). Agrowing body of evidence suggests
that 25-hydroxyvitamin D [25(OH)D], a
generally accepted indicator of vitamin D
status, is inversely associated with adipos-
ity, glucose homeostasis, lipid profiles,
and blood pressure along with its classic
role in calcium homeostasis and bone me-
tabolism (1–6). Even though the under-
lying mechanism has not been well
understood, vitamin D appears to exert
effects through direct modulation of gene
expression via vitamin D receptors
(VDRs) (1) and through regulation of ex-
tra- and intracellular calcium (1,7).
Metabolic syndrome, a constellation
of cardiometabolic disease risk factors,
has become a global epidemic (8). Several
epidemiologic studies (5,6,9,10) have
suggested that 25(OH)D status is in-
versely associated with metabolic syn-
drome in western populations, although
data for morbidly obese individuals are
inconsistent (11,12). Nevertheless, evi-
dence from the Asian population is lim-
ited. Because of ethnic differences in
vitamin D metabolism and its nutritional
status indicated by previous studies
(3,13), it is not clear whether the findings
from western populations could be ex-
trapolated directly to Asian individuals.
With rapid nutrition and lifestyle transi-
tions in the last 20 years, metabolic syn-
drome has become one of the most
widespread health problems in Asian
countries (8). However, little is known re-
garding whether vitamin D deficiency
plays an important role in the heightened
prevalence of metabolic syndrome and
other metabolic disorders among Asian
individuals. Therefore, the aim of our
study was to evaluate the plasma
25(OH)D concentration and its associa-
tion with metabolic syndrome among
Chinese individuals aged 50–70 years.
RESEARCH DESIGN AND
METHODS— The present study is a
part of the Nutrition and Health of Aging
Population in China (NHAPC) project,
which is a population-based cross-
sectional study among noninstitutional-
ized Chinese individuals aged 50 –70
years in Beijing (latitude 40° north) and
Shanghai (latitude 31° north), China. The
details of the study design have been de-
scribed previously (14). In brief, the study
was conducted simultaneously in both
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geographic locations from April to June
2005. In each city, one rural and two ur-
ban districts were selected. A total of
3,289 eligible participants (1,458 men
and 1,831 women) were recruited. After
excluding those who did not have ade-
quate blood samples for 25(OH)D mea-
surement (n  27), 3,262 individuals
were eligible for the present analysis. The
study was approved by the institutional
review board of the Institute for Nutri-
tional Sciences, and all participants pro-
vided informed consent.
Data collection
In a home interview, a standardized ques-
tionnaire was used by trained health
workers to collect information such as
age, sex, geographic location (Beijing/
Shanghai), residential region (urban/
rural), visit date (April or May/June),
education level (6, 7–9, or10 years in
school), smoking (current, former, or
never), alcohol drinking (yes/no), and
self-reported diabetes, hypertension, dys-
lipidemia, coronary heart disease (CHD),
stroke, and medication use. Physical ac-
tivity level was classified as low, moder-
ate, or high according to the International
Physical Activity Questionnaire (short last
7-day format) scoring protocol with mi-
nor modification (14). According to par-
ticipants’ responses to the corresponding
questions, family history of cardiovascu-
lar disease (CVD) or diabetes was classi-
fied as yes or no.
After the home interview, all partici-
pants were invited to attend a physical
examination after an overnight fast. Mea-
surements of weight, height, waist cir-
cumference, and blood pressure have
been described previously (14). BMI was
calculated as weight in kilograms divided
by the square of height in meters and cat-
egorized as normal weight (24.0 kg/m2)
or overweight or obesity (24.0 kg/m2),
according to the criteria for Chinese indi-
viduals (15).
Laboratory methods
Peripheral venous blood samples were
collected in tubes containing liquid EDTA
and centrifuged at 4°C. After being fro-
zen, the samples were shipped on dry ice
to the Institute for Nutritional Sciences
and stored at –80°C until analysis. Plasma
glucose, triglycerides, and HDL choles-
terol were measured enzymatically on an
automatic analyzer (Hitachi 7080) with
reagents purchased from Wako Pure
Chemical Industries (Osaka, Japan). A1C
was quantified from resolved erythrocytes
with an automated immunoassay (Tina-
quant Hemoglobin A1C II; Roche Diag-
nostics, Indianapolis, IN), which was
standardized according to the Diabetes
Control and Complications Trial/
National Glycohemoglobin Standardiza-
tion Program. Plasma high-sensitive
C-reactive protein (CRP) was measured
by a particle-enhanced immunoturbidi-
metric assay (Ultrasensitive CRP kit;
Orion Diagnostica, Espoo, Finland). In-
terleukin-6 (IL-6) was measured using a
high-sensitivity ELISA (Quantikine HS
IL-6 Immunoassay; R&D Systems, Min-
neapolis, MN). Fasting insulin was deter-
mined by radioimmunoassay (Linco
Research, St. Charles, MO). The insulin
resistance index (homeostasis model as-
sessment of insulin resistance [HOMA-
IR]) was calculated using updated
homeostasis model assessment methods
(http://www.dtu.ox.ac.uk/). The plasma
25(OH)D concentration was assayed with
a radioimmunoassay kit (DiaSorin, Still-
water, MN). Vitamin D nutritional status
was assessed as “sufficiency” (75 nmol/l),
“insufficiency” [50  25(OH)D 75
nmol/l], or “deficiency” (50 nmol/l) (1).
All of the intra- and interassay coefficients
of variation were 13%.
Definition of the metabolic
syndrome
Metabolic syndrome was defined using
the updated National Cholesterol Educa-
tion Program Adult Treatment Panel III
criteria for Asian Americans (16) as pre-
sentation of three or more of the following
components: 1) waist circumference90
cm for men or 80 cm for women; 2)
triglycerides 1.7 mmol/l; 3) HDL cho-
lesterol 1.03 mmol/l for men or 1.30
mmol/l for women; 4) blood pressure
130/85 mmHg or current use of antihy-
pertensive medications; and 5) fasting
glucose 5.6 mmol/l or previously diag-
nosed type 2 diabetes or using oral hypo-
glycemic agents or insulin.
Statistical methods
The difference in plasma 25(OH)D con-
centrations between participants with
and without metabolic syndrome was
tested by the general linear model with
controls for age, sex, geographic location,
residential region, and visit date. A logis-
tic regression model was used to evaluate
the odds ratios (ORs) and 95% CIs of hav-
ing metabolic syndrome for each quintile
of 25(OH)D compared with the highest
quintile with adjustment for potential
confounders that were suggested in pre-
vious studies (3,5,6,9,17). In addition, ef-
fects of inflammatory factors on the
association between 25(OH)D and meta-
bolic syndrome were tested by models ad-
justed for CRP and IL-6. Tests of linear
trend across increasing quintiles of
25(OH)D were performed by assigning
the median value to each quintile and
treating it as a continuous variable. A mul-
tiple linear regression model was used to
assess the association of 25(OH)D (con-
tinuous) with fasting glucose, A1C, waist
circumference, triglycerides, HDL choles-
terol, blood pressure, fasting insulin, and
HOMA-IR. A likelihood ratio test was
used to test the potential modifying effect
of sex and obesity status (24 or 24
kg/m2). When appropriate, natural log-
transformed values were used for the
analyses. Statistical inference was made
with P 0.05 (two-sided). The statistical
analyses were performed using Stata 9.2
(StataCorp, College Station, TX).
RESULTS— The geometric mean of
25(OH)D was 40.4 nmol/l in our study
participants. The percentages of vitamin
D deficiency, insufficiency, and suffi-
ciency were 69.2, 24.4, and 6.4%, respec-
tively. Across 25(OH)D quintiles,
subjects in lower 25(OH)D quintiles were
more likely to be northern (Beijing) and
urban residents, to have a physical exam-
ination in April, to have higher educa-
tional levels, and to have a family history
of CVD and diabetes. They also tended to
have an adverse cardiometabolic profile.
In addition, these subjects were less phys-
ically active and were less likely to be male
and alcohol drinkers than those in higher
25(OH)D quintiles (Table 1).
Plasma 25(OH)D concentrations
were lower in participants with metabolic
syndrome than in those without meta-
bolic syndrome (39.3 vs. 41.6 nmol/l, P
0.0001). The risk of having metabolic
syndrome increased progressively across
the highest to the lowest quintiles of
25(OH)D with the ORs of 1.31 (95% CI
1.03–1.66), 1.36 (95% CI 1.07–1.73),
1.67 (95% CI 1.31–2.13), and 1.62 (95%
CI 1.26 –2.08), respectively (Ptrend 
0.0001) (Table 2) after adjustment for
age, sex, geographic location, residential
region, and visit date (model 1). Further
controls for education, behavioral factors,
self-reported CHD, and stroke and family
history of CVD and diabetes (model 2)
did not materially change the inverse as-
sociations. After additional adjustment
for CRP and IL-6 (model 3), the ORs at-
tenuated slightly, but remained signifi-
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cant (Ptrend  0.0002). The association
appeared to be stronger in men than in
women (data not shown), although the
interaction for sex was not statistically sig-
nificant (P  0.1745). When study par-
ticipants were dichotomized with the
cutoff point of 50 nmol/l, the risk of hav-
ing metabolic syndrome was 27% higher
in those with an 25(OH)D concentration
50 nmol/l (OR 1.27; 95% CI 1.06 –
1.53) than in those with a concentration
50 nmol/l after controlling for all the
covariates in model 3.
In both simple and multiple adjusted
linear regression analyses, 25(OH)D was
inversely associated with fasting glucose,
A1C, triglycerides, waist circumference,
and diastolic blood pressure and posi-
tively associated with HDL cholesterol
(Table 3). Further adjustment for BMI
(not for waist circumference) did not sub-
stantially alter the associations. Sex-
specific interactions were observed in the
associations of 25(OH)D with triglycer-
ides and HDL cholesterol (test for inter-
action: P  0.0034 and 0.0027 for
triglycerides and HDL cholesterol, re-
spectively), and both associations were
only significant in men but not in women.
There were negative associations of
25(OH)D with fasting insulin and
HOMA-IR in the total population (P 
0.0114 and 0.0044 for insulin and
HOMA-IR, respectively), after controlling
for potential confounding factors (Table
3). We further observed a modifying ef-
fect of obesity status on these associations
(test for interaction: P  0.0363 and
0.0187 for insulin and HOMA-IR, respec-
tively). In stratified analyses, 25(OH)D
was negatively associated with fasting in-
sulin and HOMA-IR only in participants
with BMI 24 kg/m2 (P  0.0001 and
P  0.0001 for insulin and HOMA-IR,
respectively) but not in those with BMI
24 kg/m2 (P  0.5948 and 0.5874 for
insulin and HOMA-IR, respectively).
Table 1—Characteristics of study participants according to 25(OH)D quintiles
Quintiles of 25(OH)D
Q1: 28.7
nmol/l
Q2: 28.8–36.8
nmol/l
Q3: 36.9–45.5
nmol/l
Q4: 45.6–57.6
nmol/l
Q5: 57.7
nmol/l
n 652 653 652 653 652
Age (years) 58.8  6.3 58.1  6.0 58.8  5.9 58.2  5.9 59.1  5.9
Male sex 233 (35.7) 252 (38.6) 279 (42.8) 311 (47.6) 368 (56.4)
Urban residents 423 (64.9) 384 (58.8) 367 (56.3) 260 (39.8) 189 (29.0)
Residents of Beijing 466 (71.5) 419 (64.2) 331 (50.8) 238 (36.5) 168 (25.8)
Visit date (April) 433 (66.4) 389 (59.6) 334 (51.2) 245 (37.5) 183 (28.1)
Smoking
Never 395 (60.6) 422 (64.6) 423 (64.9) 409 (62.6) 376 (57.7)
Former 67 (10.3) 51 (7.8) 63 (9.7) 59 (9.0) 87 (13.3)
Current 190 (29.1) 180 (27.6) 166 (25.5) 185 (28.3) 189 (29.0)
Alcohol drinking, yes 167 (25.6) 183 (28.0) 189 (29.0) 193 (29.6) 196 (30.1)
Physical activity
Low 63 (9.7) 40 (6.1) 47 (7.2) 50 (7.7) 43 (6.6)
Moderate 310 (47.6) 307 (47.0) 294 (45.1) 228 (34.9) 230 (35.3)
High 279 (42.8) 306 (46.9) 311 (47.7) 375 (57.4) 379 (58.1)
Education
0–6 years 201 (30.8) 223 (34.2) 240 (36.8) 317 (48.6) 371 (56.9)
7–9 years 278 (42.6) 254 (38.9) 249 (38.2) 201 (30.8) 177 (27.2)
10 years 173 (26.5) 176 (27.0) 163 (25.0) 135 (20.7) 104 (16.0)
Hypertension* 373 (57.2) 372 (57.0) 367 (56.3) 329 (50.4) 344 (52.8)
Self-reported CHD† 67 (10.6) 54 (8.4) 48 (7.6) 29 (4.6) 28 (4.4)
Self-reported stroke‡ 33 (5.1) 32 (4.9) 23 (3.5) 24 (3.7) 19 (2.9)
Family history of diabetes 105 (16.1) 89 (13.6) 86 (13.2) 93 (14.2) 74 (11.4)
Family history of CVD 179 (27.5) 154 (23.6) 152 (23.3) 149 (22.8) 97 (14.9)
BMI (kg/m2) 24.9  3.8 24.9  3.8 24.6  3.6 24.3  3.2 23.5  3.3
Waist circumference (cm) 85.2  10.5 84.7  10.7 84.2  10.8 83.2  10.1 81.3  10.2
Fasting glucose (mmol/l) 5.52 (5.08–6.09) 5.46 (5.09–6.00) 5.46 (5.09–5.98) 5.42 (4.99–5.88) 5.28 (4.96–5.72)
A1C (%) 5.76 (5.46–6.22) 5.75 (5.48–6.14) 5.73 (5.46–6.10) 5.78 (5.47–6.11) 5.68 (5.39–6.02)
Insulin (pmol/l)§ 87.0 (61.2–123.0) 87.0 (60.0–120.6) 82.2 (61.2–113.4) 80.7 (59.4–106.8) 73.8 (55.2–99.3)
HOMA-IR 1.67 (1.18–2.30) 1.66 (1.17–2.26) 1.59 (1.18–2.12) 1.52 (1.14–2.02) 1.40 (1.07–1.88)
Triglycerides (mmol/l) 1.15 (0.83–1.82) 1.17 (0.82–1.80) 1.15 (0.80–1.71) 1.06 (0.73–1.61) 0.92 (0.65–1.38)
HDL cholesterol (mmol/l) 1.25  0.34 1.27  0.33 1.27  0.33 1.27  0.33 1.32  0.33
CRP (mg/l) 0.79 (0.36–1.92) 0.74 (0.35–1.68) 0.67 (0.33–1.49) 0.60 (0.32–1.37) 0.59 (0.29–1.25)
IL-6 (pg/ml)¶ 1.13 (0.73–1.86) 1.07 (0.73–1.65) 1.00 (0.62–1.49) 1.06 (0.69–1.57) 0.94 (0.61–1.49)
Data are means SD, n (%), or median (interquartile range). *Blood pressure140/90 mmHg, or current use of anti-hypertensive medications. †77 participants
were excluded with a missing value for self-reported CHD. ‡10 participants were excluded with a missing value for self-reported stroke. §4 participants were
excluded with a missing value of fasting insulin. 23 participants were excluded with a missing value for HOMA-IR. ¶89 participants were excluded with a missing
value for IL-6.
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When overweight and obese participants
were divided into 25(OH)D quintiles, the
multivariate-adjusted geometric mean of
fasting insulin was 13.86 pmol/l lower
(P  0.0003) and HOMA-IR was 0.26
lower (P 0.0002) for the participants in
the highest quintile compared with those
in the lowest. Excluding those with diag-
nosed diabetes and CVD yielded similar
results patterns (data not shown).
CONCLUSIONS— We observed that
94% of our study participants had
25(OH)D deficiency or insufficiency. A
lower 25(OH)D concentration was associ-
ated with increased risk of having metabolic
syndrome and its individual components.
In addition, poor 25(OH)D status was also
significantly associated with increased insu-
lin resistance, especially among those who
were overweight or obese.
Table 2—Adjusted ORs (95% CI) of having metabolic syndrome according to quintiles of plasma 25(OH)D concentrations
Quintiles of 25(OH)D
Ptrend
Q5: 57.7
nmol/l
Q4: 45.6–57.6
nmol/l
Q3: 36.9–45.5
nmol/l
Q2: 28.8–36.8
nmol/l
Q1: 28.7
nmol/l
No. cases/participants 193/652 248/653 279/652 326/653 335/652
Model 1 1.00 (reference) 1.31 (1.03–1.66) 1.36 (1.07–1.73) 1.67 (1.31–2.13) 1.62 (1.26–2.08) 0.0001
Model 2 1.00 (reference) 1.31 (1.02–1.66) 1.38 (1.08–1.77) 1.76 (1.37–2.26) 1.64 (1.27–2.13) 0.0001
Model 3 1.00 (reference) 1.28 (1.00–1.64) 1.33 (1.03–1.71) 1.71 (1.32–2.21) 1.52 (1.17–1.98) 0.0002
Model 1: adjusted for age, sex, geographic location (Beijing/Shanghai), residential region (urban/rural), and visit date (April or May/June). Model 2: further adjusted
for education (6, 7–9, or10 years in school), physical activity (low, moderate, or high), smoking (current, former, or never), alcohol drinking (yes/no), family
history of CVD (yes/no) and diabetes (yes/no), and self-reported CHD (yes/no) and stroke (yes/no). Model 3: further adjusted for inflammatory factors (CRP and
IL-6).
Table 3—Adjusted regression coefficients of 25(OH)D with components of metabolic syndrome, A1C, fasting insulin, and HOMA-IR
Model 1 Model 2 Model 3 Model 4
 (SEM) P  (SEM) P  (SEM) P  (SEM) P
All (N  3,262)
Fasting glucose (mmol/l) 0.17 (0.08) 0.0277 0.17 (0.08) 0.0337 0.18 (0.08) 0.0262 0.17 (0.08) 0.0281
A1C (%) 0.21 (0.05) 0.0001 0.20 (0.05) 0.0001 0.21 (0.05) 0.0001 0.21 (0.05) 0.0001
Fasting insulin (pmol/l)* 0.08 (0.02) 0.0004 0.07 (0.02) 0.0036 0.06 (0.02) 0.0088 0.06 (0.02) 0.0114
HOMA-IR† 0.09 (0.02) 0.0002 0.07 (0.02) 0.0014 0.07 (0.02) 0.0035 0.06 (0.02) 0.0044
Waist circumference (cm) 1.61 (0.46) 0.0005 1.64 (0.47) 0.0005 1.46 (0.48) 0.0023 — —
Triglycerides (mmol/l)‡ 0.13 (0.03) 0.0001 0.12 (0.03) 0.0001 0.11 (0.03) 0.0001 0.10 (0.03) 0.0001
HDL cholesterol (mmol/l)§ 0.07 (0.01) 0.0001 0.07 (0.02) 0.0001 0.06 (0.02) 0.0001 0.06 (0.01) 0.0001
Diastolic blood pressure
(mmHg) 1.29 (0.48) 0.0072 1.32 (0.49) 0.0074 1.25 (0.50) 0.0122 1.15 (0.48) 0.0169
Systolic blood pressure
(mmHg) 1.37 (0.95) 0.1486 1.52 (0.98) 0.1185 1.28 (0.99) 0.1964 1.08 (0.95) 0.2577
Sex
Men (n  1,443)
Triglycerides (mmol/l) 0.19 (0.04) 0.0001 0.19 (0.04) 0.0001 0.19 (0.04) 0.0001 0.19 (0.04) 0.0001
HDL cholesterol (mmol/l) 0.10 (0.02) 0.0001 0.10 (0.02) 0.0001 0.10 (0.02) 0.0001 0.10 (0.02) 0.0001
Women (n  1,819)
Triglycerides (mmol/l) 0.07 (0.04) 0.0574 0.04 (0.04) 0.2554 0.03 (0.04) 0.4546 0.02 (0.03) 0.5907
HDL cholesterol (mmol/l) 0.03 (0.02) 0.0841 0.03 (0.02) 0.1182 0.02 (0.02) 0.3121 0.02 (0.02) 0.4327
Obesity status
BMI 24 kg/m2 (n  1,526)
Fasting insulin (pmol/l) 0.04 (0.03) 0.2653 0.03 (0.03) 0.4596 0.02 (0.04) 0.5948 — —
HOMA-IR 0.03 (0.03) 0.2977 0.02 (0.03) 0.4530 0.02 (0.03) 0.5874 — —
BMI 24 kg/m2 (n  1,736)
Fasting insulin (pmol/l) 0.14 (0.03) 0.0001 0.13 (0.03) 0.0001 0.12 (0.03) 0.0001 — —
HOMA-IR 0.15 (0.03) 0.0001 0.13 (0.03) 0.0001 0.13 (0.03) 0.0001 — —
25(OH)D, fasting insulin, HOMA-IR, and triglycerides were log-transformed before analysis. Model 1: adjusted for age, sex (not for sex-stratified analysis),
geographic location (Beijing/Shanghai), residential region (urban/rural), and visit date (April or May/June). Model 2: further adjusted for education (6, 7–9, or10
years in school), physical activity (low, moderate, or high), smoking (current, former, or never), alcohol drinking (yes/no), family history of CVD (yes/no) and
diabetes (yes/no), and self-reported CHD (yes/no) and stroke (yes/no). For fasting glucose, A1C, fasting insulin, and HOMA-IR, hypertension (yes/no) was included
in the model. Model 3: further adjusted for inflammatory factors (CRP and IL-6, continuous variables). Model 4: further adjusted for BMI (not for waist circumference
and obesity status-stratified analysis). *4 participants were excluded with a missing value of fasting insulin; P for interaction between 25(OH)D and obesity status
0.0363. †23 participants were excluded with a missing value of HOMA-IR; P for interaction between 25(OH)D and obesity status  0.0187. §P for interaction
between 25(OH)D and sex  0.0034. §P for interaction between 25(OH)D and sex  0.0027.
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Although two studies reported that
the VDR gene polymorphism was not as-
sociated with metabolic syndrome
(18,19), the inverse association between
25(OH)D and metabolic syndrome found
in our study is consistent with that from
three previous cross-sectional reports in
American (9,10) and British adults (6).
These three studies (6,9,10) were also
performed in the general population with
large sample sizes; two American studies
(9,10) included subjects aged 20 years
and the other one (6) comprised partici-
pants aged 45 years. In these studies
(6,9,10), 25(OH)D concentrations were
relatively higher than in our study. A co-
hort study by Forouhi et al. (5) showed
that the baseline concentration of
25(OH)D was inversely associated with
an increased metabolic syndrome risk z
score. However, a study in southern Cal-
ifornia residents (17) did not show a sig-
nificant association between 25(OH)D
and metabolic syndrome, which may be
attributed to extraordinary high levels of
25(OH)D (mean concentration was 108.9
nmol/l in men and 101.6 nmol/l in
women). Whether there is a threshold or a
specific range for the association between
25(OH)D and metabolic abnormalities
merits further investigation.
Elevated CRP and IL-6 levels have
been found to be positively associated
with metabolic syndrome (8) and in-
versely correlated with 25(OH)D in our
study and other studies (20). Thus, we
further explored whether the observed in-
verse association between 25(OH)D and
metabolic syndrome was mediated by
CRP and/or IL-6. In our study, the asso-
ciation was slightly attenuated but re-
mained significant after we control for
CRP and IL-6. Our result was in accor-
dance with the data from the Third Na-
tional Health and Nutrition Examination
Survey (NHANES III) (9) in which
25(OH)D was inversely associated with
metabolic syndrome independent of CRP
levels.
25(OH)D status in our study was
shown to be inversely associated with
A1C and individual metabolic syndrome
features such as fasting glucose, waist cir-
cumference, diastolic blood pressure, and
triglycerides and positively associated
with HDL cholesterol. However, unlike
some of the previous studies (6,9,10), we
have noticed that plasma 25(OH)D was
associated with triglycerides and HDL
cholesterol only in men but not in
women. These sex-specific associations
may par t ly expla in the s t ronger
25(OH)D–metabolic syndrome associa-
tion in men than in women in our study.
Although the mechanistic role of vitamin
D deficiency in the pathogenesis of dys-
lipidemia is not well understood, vitamin
D supplementation was reported to atten-
uate the beneficial effect of hormone re-
placement therapy on serum lipid levels
(21). Thus, the potential sex-specific ef-
fects of vitamin D on metabolic disorders
need to be elucidated further.
Insulin resistance is a major underly-
ing mechanism for the metabolic syn-
drome. Experimental studies have
suggested that vitamin D may exert its
beneficial effects by stimulating the ex-
pression of insulin receptor to improve
insulin responsiveness for glucose trans-
port or by controlling calcium influx,
which is essential for the insulin-
mediated intracellular process in insulin-
responsive tissues (7). Most epide-
miologic studies (3,5,19), but not all
(18), suggested that serum 25(OH)D or
the VDR polymorphism was associated
with insulin sensitivity. Moreover, data
from NHANES III documented an ethnic
difference in the association between
25(OH)D and insulin resistance (4), with
a stronger association in Caucasians than
in African Americans, who have much
lower levels of 25(OH)D concentrations.
Interestingly, in our population, with
25(OH)D levels similar to those of African
Americans, 25(OH)D was also negatively
associated with fasting insulin and
HOMA-IR, and the associations were
stronger among overweight and obese
subjects.
Obesity is known to be associated
with decreased bioavailability of vitamin
D, which is sequestered in body fat (2). In
fact, Forouhi et al. (5) reported a signifi-
cant interaction between 25(OH)D and
BMI on the risk for a 10-year increase in
HOMA-IR. In addition, the release of free
fatty acids from adipose tissue can induce
insulin resistance, whereas 1,25-
dihydroxyvitamin D has been shown to
counteract the free fatty acid–induced in-
sulin resistance (22). The stronger associ-
ation of vitamin D with insulin resistance
among the overweight and obese partici-
pants suggests that adequate vitamin D
status is more important for the preven-
tion of insulin resistance and metabolic
syndrome in these individuals.
Our data suggested that vitamin D de-
ficiency was common in middle-aged and
elderly Chinese individuals [i.e., 69.2%
participants with 25(OH)D50 nmol/l].
Indeed, poor vitamin D status in middle
and older Chinese individuals was also
reported previously in two small bone-
related studies conducted in Beijing (23)
and Shenyang (24), respectively. Al-
though little is known regarding to what
extent the high prevalence of vitamin D
deficiency in our population could be ex-
plained by certain environmental and/or
genetic factors, plausible explanations in-
clude 1) the skin of elderly individuals is
less efficient for forming vitamin D3, the
major precursor of 25(OH)D (25), 2) use
of vitamin D supplements is rare among
older Chinese individuals (24), 3) unlike
in the United States and other western
countries, few vitamin D–fortified foods
are available in China, and 4) our study
participants were from a relatively high
latitude, especially those in Beijing (lati-
tude 40° north), who had lower 25(OH)D
levels than their Shanghai counterparts
(median 35.6 nmol/l in Beijing vs. 47.6
nmol/l in Shanghai). Hence, attention
should be paid to improving vitamin D
nutritional status in the Chinese popula-
tion, particularly for those who are older,
female, obese, less physically active, and
living in high latitudes and urban areas.
To our knowledge, this is the first
study to investigate the distribution and
association of 25(OH)D levels with meta-
bolic syndrome in Chinese individuals.
The major strength of this study is that we
used the data from a large representative
sample of middle-aged and older men and
women living in the two largest munici-
palities in China. Our analyses took into
account many potential covariates that
might confound the observed associa-
tions. Furthermore, we completed the
field study within a relatively short pe-
riod, which minimized the seasonal vari-
ation in the biomarkers. Nevertheless,
several limitations should be acknowl-
edged. A cause-effect relationship be-
tween 25(OH)D and metabolic syndrome
cannot be inferred because of the cross-
sectional nature of the study design. Al-
though data on sun exposure and vitamin
D supplementation were not available, we
used a direct measure of vitamin D status,
which reflects cumulative sun exposure
and dietary vitamin D intake. In addition,
because we did not measure serum cal-
cium and parathyroid hormone, we could
not determine whether the association of
25(OH)D with metabolic syndrome was
partly mediated by calcium or secondary
hyperparathyroidism. However, data
from NHANES 2003–2004 (10) and the
Medical Research Council Ely Prospective
Study (5) suggested that the associations
25(OH)D and metabolic syndrome
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between 25(OH)D and insulin resistance
and metabolic syndrome were indepen-
dent of calcium and parathyroid
hormone.
In summary, our findings suggested
that reduced 25(OH)D is associated with
an increased risk of having metabolic syn-
drome and adverse values for metabolic
syndrome components. The association
of 25(OH)D with insulin resistance is
stronger in overweight and obese individ-
uals than in normal-weight individuals.
Because there is evidence of ethnic varia-
tions in the 25(OH)D effect and limited
data on the association of 25(OH)D with
metabolic syndrome in Asians, our data
provide novel insights into the nature of
this association among Asians. Moreover,
because of the high prevalence of meta-
bolic syndrome and vitamin D deficiency
in the middle-aged and elderly Chinese
population, our results may have impor-
tant public health implications. Increased
sun exposure and use of vitamin D sup-
plements or fortified foods are simple and
inexpensive means to prevent vitamin D
deficiency and related health problems.
Nevertheless, the benefits of vitamin D on
metabolic syndrome and related diseases
such as type 2 diabetes need to be con-
firmed in future prospective studies and
clinical trials.
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